# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-03-31T12:07:23.967930

---

**Idea Fidelity**

The paper largely pursues the manifest idea of using queue congestion at NHTSA to identify a triage effect on recall outcomes. It relies on the same data sources (ODI investigations, complaints, recalls), highlights the fixed-capacity constraint (≈90 investigators over 280 million vehicles), and focuses on the causal channel where concurrent investigations at other firms reduce examiner bandwidth. However, the paper deviates in two important respects. First, Figure 1 (and the accompanying text) describe a much smaller analysis sample—1,362 investigations—than the 5,330 investigations advertised in the Idea Manifest, without explaining the attrition. Second, while the manifest emphasized an instrumental-variables strategy, the paper settles mainly for reduced-form estimates and only relegates the IV to the appendix, citing weak first-stage power. These departures should be justified explicitly to ensure the paper remains faithful to the originally proposed contribution.

---

**Summary**

The paper documents that higher queue congestion—measured by concurrent open ODI investigations at other manufacturing groups—reduces the probability that a new safety investigation leads to a recall. The effect is concentrated in Preliminary Evaluations and is accompanied by shorter investigation durations, consistent with investigators triaging lower-severity cases when bandwidth is constrained. The results persist across alternative clustering choices, manufacturer leave-one-out samples, and survive the inclusion of controls for complaint-based severity and component category year effects.

---

**Essential Points**

1. **Endogeneity of the “Other-Manufacturer Queue.”** The exclusion restriction requires that the timing of investigations at other manufacturers affects the focal investigation only through examiner workload. But industry-wide shocks (e.g., macroeconomic conditions, widespread new models, regulatory scrutiny spikes) can simultaneously raise complaints across manufacturers and alter NHTSA’s behavior. Year fixed effects may not absorb such shocks if they differ by component or if they coincide with bursts of investigations. The paper needs stronger evidence that the instrument is as-good-as-random—e.g., using event study/lead specifications, placebo checks on outcomes measured before the current investigation opens, or showing that queue fluctuations predict nothing about earlier-period severity or complaints.

2. **Interpretation of the Reduced-Form Effect.** The paper interprets the negative coefficient on other-manufacturer queue as a triage-driven increase in forgoing recalls. However, the reduced-form effect may capture other mechanisms—such as endogenous investigation selection, capacity-driven changes in documentation quality, or manufacturer response—to which the paper currently gives only cursory treatment. A stronger case for triage requires: (i) more direct evidence that investigators are altering their decisions rather than complaints being resolved elsewhere; (ii) discussion of whether manufacturers might “lean on” NHTSA when the queue is short to push through recalls; and (iii) sensitivity checks showing that the queue does not predict other investigation inputs (e.g., complaint severity in the immediately preceding weeks).

3. **External Validity and Welfare Implications.** The paper claims policy relevance by extrapolating from the reduced-form effect to forgone recalls and implied safety costs, yet it stops short of quantifying downstream outcomes (e.g., actual injuries avoided per recall). Without that link—especially since the instrument only shifts investigation timing rather than recall completion—it is difficult to assess the welfare magnitude. The paper should discuss the assumptions behind the “65 forgone recalls” calculation and whether its sample (only closed PEs/EAs, to 2024) is representative of all investigations and recalls.

Because these issues strike at identification and interpretation, they must be resolved before publication.

---

**Suggestions**

1. **Clarify the Sample and Attrition.** The manifest promised 5,330 investigations, whereas the paper analyzes 1,362. Readers need to understand this discrepancy. Is the sample limited to closed PEs/EAs, after dropping investigations with missing data, or are there other exclusions (e.g., investigations without complaints)? Provide a clear flowchart (appendix table) describing how the 153,998 investigation-make-model records collapse to the final sample. This transparency would also help readers assess potential selection bias (e.g., are more severe or more recent cases disproportionately excluded?).

2. **Bolster the Instrumental Argument.** Even if the reduced-form is your preferred specification, devote more attention to the plausibility of the excluded variation. Consider adding the following:

   - **Balancing Tests:** Show that the other-manufacturer queue at the opening date is uncorrelated with pre-opening shocks, such as cumulative complaints for the focal manufacturer or macro vehicle safety news coverage. If the queue is predictable only by exogenous arrival of other-manufacturer defects, this strengthens the IV story.

   - **Lead/Lag Analysis:** Estimate regressions of future queue congestion on past investigation outcomes (and vice versa). If future queue length is unrelated to past recalls, that supports the interpretation that queue shocks are not driven by the focal investigation.

   - **Alternative Instruments:** If feasible, consider instruments based on scheduled large investigations (e.g., known safety crisis episodes) or use timing of other-manufacturer investigations from different segments (commercial vs. passenger vehicles) to show robustness.

3. **Distinguish Triage from Delay.** The paper argues that congestion shortens investigations and reduces recall probability, suggesting abandonment rather than delay. This is interesting, but the mechanism would be clearer with more granular timing data. For example, can you show that investigations closed without recall under congestion have fewer manufacturer communications, shorter testing phases, or earlier closures than comparable investigations in quiet periods? Even descriptive statistics showing distributions of closure durations by recall status and queue length would be helpful.

4. **Revisit Severity Heterogeneity.** Table 3’s severity split yields a puzzling result: high-severity cases still exhibit a negative effect on recall probability even with capacity pressure. If triage is rational, one might expect little to no effect for severe defects (as suggested in the duration analysis). Consider refining the severity measure—for instance, restricting to cases with confirmed injuries/deaths before the investigation opens, or using a severity scale derived from the costliness of the eventual recall. Alternatively, explore whether the effect differs by component category or USDOT-critical failures to illustrate whether somehow systemic shocks overwhelm triage prioritization.

5. **Expand Discussion of Policy Implications.** The end of the paper suggests staffing increases to reduce the triage tax. It would be useful to connect the reduced-form effects to actual resources—for instance, how many investigators would need to be added to reduce the queue by 10 investigations, given the average caseload per investigator? Also, given the triage tax is concentrated in PEs, is the relevant policy lever better data triage, better preliminary evaluation tools, or simply more staff? These clarifications would make the policy contribution more actionable.

6. **Address Weak First Stage More Thoroughly.** Briefly discuss why the IV first stage is weak (F=4.0 with year FEs but apparently much higher in the appendix table), and whether alternative specifications (e.g., excluding year fixed effects) strengthen the instrument. Even if you keep the reduced-form as the centerpiece, explicitly stating the limits of the IV and defending the reduced-form interpretation mitigates reader concerns about causal claims.

7. **Consider Outcome Robustness.** The recall indicator lumps together recalls of very different sizes and severities. If possible, explore outcomes such as (i) number of vehicles affected by recalls, (ii) whether recalls were voluntary or forced, or (iii) downstream injuries over some horizon. Even if data limitations prevent full estimation, a brief discussion of how these different outcomes might align with or diverge from the recall probability effect would enrich the narrative.

Implementing these suggestions would strengthen the identification story, clarify the mechanism, and ground the policy implications in the data, making the paper a more persuasive addition to the literature on regulatory capacity and auto safety.
